Summit Therapeutics

Summit Therapeutics

Summit's lead molecule, ivonescimab, is a bispecific antibody combining the effects of immunotherapy via anti-PD-1 with the anti-angiogenesis effects associated w blocking VEGF into a single molecule. Ivonescimab displays cooperative binding to its intended targets w higher affinity when in the presence of PD-1 & VEGF. Globally 1,600+ patients have been treated w ivonescimab across Summit & Akeso clinical trials. Summit is enrolling two Phase III NSCLC clinical trials: NCT05184712/NCT05899608 / Summit's Mission: To resolve serious unmet medical needs for the betterment of overall human health.

Yes

Lung Cancer, Biotechnology, Clinical Trials, Immunotherapy, Pharmaceutical

Yes